Comparative Pharmacology
Head-to-head clinical analysis: LOMAIRA versus MERIDIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMAIRA versus MERIDIA.
LOMAIRA vs MERIDIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lomitapide inhibits microsomal triglyceride transfer protein (MTP), which is responsible for the assembly and secretion of apolipoprotein B-containing lipoproteins in the liver and intestine, thereby reducing plasma levels of LDL-C, triglycerides, and other lipids.
Sibutramine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that inhibits the reuptake of serotonin and norepinephrine in the hypothalamus, enhancing satiety and increasing energy expenditure.
100 mg orally once daily, with or without food.
10–15 mg orally once daily, titrated to 15 mg maximum after 4 weeks if inadequate weight loss.
None Documented
None Documented
Terminal elimination half-life: 12 hours; clinical context: steady-state achieved in 2-3 days.
Sibutramine: 1.1 hours; active metabolites M1 and M2: 14-16 hours (terminal half-life). Steady-state achieved within 4 days.
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other.
Primarily hepatic (CYP3A4 metabolism) with renal excretion of metabolites; ~80% of dose excreted in urine (mainly as M1 and M2 metabolites) and ~10% in feces.
Category C
Category C
Appetite Suppressant
Appetite Suppressant